StockNews.com assumed coverage on shares of Avinger (NASDAQ:AVGR – Free Report) in a research note published on Thursday morning. The firm issued a hold rating on the medical device company’s stock.
Avinger Stock Performance
Avinger stock opened at $0.97 on Thursday. Avinger has a fifty-two week low of $0.83 and a fifty-two week high of $5.89. The firm’s 50-day simple moving average is $1.06 and its 200 day simple moving average is $2.03. The stock has a market cap of $1.65 million, a PE ratio of -0.05 and a beta of 1.17.
Avinger (NASDAQ:AVGR – Get Free Report) last released its earnings results on Thursday, August 8th. The medical device company reported ($2.82) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($2.39). The firm had revenue of $1.85 million during the quarter, compared to the consensus estimate of $2.55 million. As a group, analysts predict that Avinger will post -4.69 EPS for the current fiscal year.
Institutional Inflows and Outflows
About Avinger
Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.
Featured Stories
- Five stocks we like better than Avinger
- About the Markup Calculator
- Taiwan Semiconductor Soars on Earnings With More Room to Run
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Is Lucid Group Nearing the Bottom? What Investors Should Know
- How is Compound Interest Calculated?
- 90% Gain Possible? Analysts Are Bullish on Joby Aviation
Receive News & Ratings for Avinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avinger and related companies with MarketBeat.com's FREE daily email newsletter.